Genentech vs CropX
Side-by-side comparison of AI visibility scores, market position, and capabilities
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
$3.5M annual revenue 2025; $86.1M total funding (Series C Oct 2023); deployed in 60+ countries; acquired Regen adding 130K acres; 134 employees; precision agriculture market $8.7B 2024; subscription-based model
About
CropX was founded in 2014 in Tel Aviv, Israel, with the mission of helping farmers improve crop yields and reduce resource consumption through precision agriculture technology. The company developed soil sensing hardware and analytics software that translate subsurface soil data into actionable irrigation and nutrient management recommendations, enabling farms of any size to optimize inputs based on actual field conditions rather than generalized agronomic guidelines.\n\nCropX's platform combines wireless soil sensors that measure moisture, temperature, and electrical conductivity at multiple depths with a cloud-based analytics engine that integrates weather data, satellite imagery, and farm management records. Recommendations are delivered via a mobile app, enabling farm managers to make data-driven irrigation decisions in real time. The 2023 acquisition of Regen added 130,000 acres of managed farmland to its platform and expanded its capabilities in carbon and regenerative agriculture. CropX is deployed in 60+ countries across a diverse range of crops and farm types.\n\nCropX has raised $86.1M in total funding, including a Series C in October 2023, and has grown to serve 20,000+ customers with a team of 134 employees. The company's international deployment footprint — spanning North America, Europe, Australia, and emerging agricultural markets — reflects the universal applicability of data-driven soil management. CropX sits at the intersection of precision agriculture, water conservation, and sustainable farming, three of the highest-priority investment themes in global food systems.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.